119 related articles for article (PubMed ID: 16497631)
21. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
[TBL] [Abstract][Full Text] [Related]
22. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
[TBL] [Abstract][Full Text] [Related]
23. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver.
Fishbein MH; Stevens WR
Pediatr Radiol; 2001 Nov; 31(11):806-9. PubMed ID: 11692239
[TBL] [Abstract][Full Text] [Related]
24. Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis.
Tarantino G; Conca P; Coppola A; Vecchione R; Di Minno G
Eur J Clin Invest; 2007 Jan; 37(1):48-53. PubMed ID: 17181567
[TBL] [Abstract][Full Text] [Related]
25. The trouble with biopsies..
Baumann U; McKiernan PJ; Kelly DA
J Pediatr Gastroenterol Nutr; 2006 Jul; 43(1):122. PubMed ID: 16819390
[No Abstract] [Full Text] [Related]
26. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.
Lydatakis H; Hager IP; Kostadelou E; Mpousmpoulas S; Pappas S; Diamantis I
Liver Int; 2006 Sep; 26(7):864-71. PubMed ID: 16911470
[TBL] [Abstract][Full Text] [Related]
27. Implications of elevated serum alanine aminotransferase levels: think outside the liver.
Ioannou GN
Gastroenterology; 2008 Dec; 135(6):1851-4. PubMed ID: 19007778
[No Abstract] [Full Text] [Related]
28. [Nonalcoholic steatohepatitis: a clinicopathological analysis of liver biopsy in 32 cases].
Meng JR; Zheng RD; Zhang MF; Guo YH; Lin MZ; Dai TJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):339-41. PubMed ID: 16546742
[TBL] [Abstract][Full Text] [Related]
29. Effect of disease progression on liver apparent diffusion coefficient values in a murine model of NASH at 11.7 Tesla MRI.
Anderson SW; Soto JA; Milch HN; Ozonoff A; O'Brien M; Hamilton JA; Jara HJ
J Magn Reson Imaging; 2011 Apr; 33(4):882-8. PubMed ID: 21448953
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
[TBL] [Abstract][Full Text] [Related]
31. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.
Preiss D; Sattar N
Clin Sci (Lond); 2008 Sep; 115(5):141-50. PubMed ID: 18662168
[TBL] [Abstract][Full Text] [Related]
32. Keratin-18 as a marker of steatohepatitis.
Gonzalez-Quintela A; Lojo S; Otero E; Perez LF
Hepatology; 2007 Feb; 45(2):545. PubMed ID: 17256723
[No Abstract] [Full Text] [Related]
33. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
34. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy.
Mennesson N; Dumortier J; Hervieu V; Milot L; Guillaud O; Scoazec JY; Pilleul F
J Comput Assist Tomogr; 2009; 33(5):672-7. PubMed ID: 19820490
[TBL] [Abstract][Full Text] [Related]
35. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Miele L; Forgione A; Gasbarrini G; Grieco A
Transl Res; 2007 Mar; 149(3):114-25. PubMed ID: 17320797
[TBL] [Abstract][Full Text] [Related]
37. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
38. Biochemical markers: the road map for the diagnosis of nonalcoholic fatty liver disease.
Ahmed MH
Am J Clin Pathol; 2007 Jan; 127(1):20-2. PubMed ID: 17145635
[No Abstract] [Full Text] [Related]
39. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
[TBL] [Abstract][Full Text] [Related]
40. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
